Morse Asset Management Inc Purchases 412 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Morse Asset Management Inc boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,452 shares of the medical equipment provider’s stock after acquiring an additional 412 shares during the quarter. Intuitive Surgical accounts for approximately 1.8% of Morse Asset Management Inc’s investment portfolio, making the stock its 17th biggest holding. Morse Asset Management Inc’s holdings in Intuitive Surgical were worth $6,965,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Baystate Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC increased its holdings in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares during the last quarter. Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at $28,000. Delos Wealth Advisors LLC grew its stake in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ISRG has been the topic of several research reports. Citigroup upped their price target on shares of Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Robert W. Baird upped their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. BTIG Research upped their price objective on shares of Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Evercore ISI cut their price objective on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $438.74.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares of the company’s stock, valued at approximately $343,628.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $136,522.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,358 shares of company stock valued at $5,592,694. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $4.56 during trading hours on Friday, reaching $441.30. The company’s stock had a trading volume of 1,196,597 shares, compared to its average volume of 1,795,967. The firm has a fifty day simple moving average of $427.82 and a 200-day simple moving average of $398.79. The stock has a market cap of $156.82 billion, a P/E ratio of 79.66, a P/E/G ratio of 4.86 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business earned $1.18 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.